

Ian F Pollack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8026334/publications.pdf>

Version: 2024-02-01

141
papers

8,298
citations

53794

45
h-index

49909

87
g-index

143
all docs

143
docs citations

143
times ranked

9476
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
2	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	10.7	582
3	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
4	Mutism and Pseudobulbar Symptoms after Resection of Posterior Fossa Tumors in Children. <i>Neurosurgery</i> , 1995, 37, 885-892.	1.1	357
5	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1011-1022.	10.7	315
6	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
7	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
8	A Randomized, Controlled Study of a Programmable Shunt Valve versus a Conventional Valve for Patients with Hydrocephalus. <i>Neurosurgery</i> , 1999, 45, 1399-1411.	1.1	240
9	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. <i>Neuro-Oncology</i> , 2017, 19, 1135-1144.	1.2	236
10	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. <i>Journal of Experimental Medicine</i> , 2018, 215, 141-157.	8.5	186
11	Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1. <i>Neuro-Oncology</i> , 2007, 9, 145-160.	1.2	169
12	Childhood brain tumors: current management, biological insights, and future directions. <i>Journal of Neurosurgery: Pediatrics</i> , 2019, 23, 261-273.	1.3	169
13	Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 974-983.	1.6	154
14	Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. <i>Cancer</i> , 1989, 63, 939-947.	4.1	153
15	IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. <i>Child's Nervous System</i> , 2011, 27, 87-94.	1.1	152
16	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	27.8	129
17	EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines. <i>Neoplasia</i> , 2005, 7, 717-722.	5.3	126
18	Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. <i>Pediatric Neurology</i> , 2015, 53, 31-46.	2.1	125

#	ARTICLE	IF	CITATIONS
19	Correlation of Neurosurgical Subspecialization with Outcomes in Children with Malignant Brain Tumors. <i>Neurosurgery</i> , 2000, 47, 879-887.	1.1	123
20	Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. <i>Neuro-Oncology</i> , 2016, 18, 1442-1450.	1.2	111
21	Childhood brain tumors: epidemiology, current management and future directions. <i>Nature Reviews Neurology</i> , 2011, 7, 495-506.	10.1	110
22	A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium. <i>Neuro-Oncology</i> , 2011, 13, 290-297.	1.2	110
23	Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. <i>Journal of Neurosurgery: Pediatrics</i> , 2011, 8, 135-148.	1.3	108
24	The Molecular Biology of Ependymomas. <i>Brain Pathology</i> , 1997, 7, 807-822.	4.1	105
25	Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333. <i>Journal of Clinical Oncology</i> , 2020, 38, 1175-1185.	1.6	102
26	Targeted next-generation sequencing panel (GliSeq) provides comprehensive genetic profiling of central nervous system tumors. <i>Neuro-Oncology</i> , 2016, 18, 379-387.	1.2	101
27	Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. <i>Journal of Neurosurgery: Pediatrics</i> , 2006, 105, 418-424.	1.3	99
28	Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. <i>Clinical Cancer Research</i> , 2002, 8, 2851-5.	7.0	99
29	Pediatric brain tumors. <i>Journal of Surgical Oncology</i> , 1999, 16, 73-90.	1.4	93
30	Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2685-2697.	1.6	91
31	Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. <i>Cancer</i> , 2016, 122, 1928-1936.	4.1	90
32	A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. <i>Cancer</i> , 2001, 91, 417-422.	4.1	88
33	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018, 20, 13-23.	1.2	74
34	The Effect of Early Craniocervical Decompression on Functional Outcome in Neonates and Young Infants with Myelodysplasia and Symptomatic Chiari II Malformations: Results from a Prospective Series. <i>Neurosurgery</i> , 1996, 38, 703-710.	1.1	73
35	Neurogenic Dysphagia Resulting from Chiari Malformations. <i>Neurosurgery</i> , 1992, 30, 709-719.	1.1	72
36	The role of surgery in pediatric gliomas. , 1999, 42, 271-288.		72

#	ARTICLE	IF	CITATIONS
37	Stereotactic radiosurgery for pilocytic astrocytomas part 2: outcomes in pediatric patients. <i>Journal of Neuro-Oncology</i> , 2009, 95, 219-229.	2.9	70
38	A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 443-451.	2.9	69
39	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1157-1168.	1.2	69
40	Chiari Malformation and Sleep-Disordered Breathing: A Review of Diagnostic and Management Issues. <i>Sleep</i> , 2000, 23, 1-7.	1.1	68
41	The Treatment of Intracranial Malignant Gliomas Using Orally Administered Tamoxifen Therapy. <i>Neurosurgery</i> , 1992, 30, 897-903.	1.1	61
42	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. <i>JAMA Oncology</i> , 2021, 7, 1313.	7.1	61
43	Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. <i>Neuro-Oncology</i> , 2016, 18, 725-734.	1.2	60
44	Identification of Interleukin-13 Receptor $\alpha 2$ Peptide Analogues Capable of Inducing Improved Antiglioma CTL Responses. <i>Cancer Research</i> , 2006, 66, 5883-5891.	0.9	59
45	Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , The, 2020, 21, e330-e336.	10.7	59
46	Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. <i>Molecular Carcinogenesis</i> , 2013, 52, 118-133.	2.7	56
47	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. <i>Journal of Neuro-Oncology</i> , 2016, 130, 517-527.	2.9	49
48	Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	49
49	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47
50	Proliferation index as a predictor of prognosis in malignant gliomas of childhood. <i>Cancer</i> , 1997, 79, 849-856.	4.1	43
51	Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. <i>Journal of Neuro-Oncology</i> , 2010, 99, 155-163.	2.9	41
52	Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. <i>Neuro-Oncology</i> , 2017, 19, now158.	1.2	41
53	Neurofibromatosis 1 and 2. <i>Brain Pathology</i> , 1997, 7, 823-836.	4.1	39
54	The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. , 1997, 31, 255-266.		35

#	ARTICLE	IF	CITATIONS
55	Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 354-365.	2.5	35
56	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
57	Inhibition of Phosphatidylinositol 3-Kinase/AKT Signaling by NVP-BKM120 Promotes ABT-737-Induced Toxicity in a Caspase-Dependent Manner through Mitochondrial Dysfunction and DNA Damage Response in Established and Primary Cultured Glioblastoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 22-35.	2.5	32
58	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 637146.	4.8	32
59	Surgical treatment of sagittal synostosis by extended strip craniectomy: Cranial index, nasofrontal angle, reoperation rate, and a review of the literature. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2014, 42, 1095-1101.	1.7	31
60	Surgical Management of Spinal Cord Compression from Plexiform Neurofibromas in Patients with Neurofibromatosis 1. <i>Neurosurgery</i> , 1998, 43, 248-255.	1.1	29
61	Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1066-1071.	1.5	24
62	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
63	Special issues in the management of gliomas in children with neurofibromatosis 1. <i>Journal of Neuro-Oncology</i> , 1996, 28, 257-68.	2.9	22
64	Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. <i>Journal of Neuro-Oncology</i> , 1999, 41, 9-20.	2.9	21
65	The current landscape of immunotherapy for pediatric brain tumors. <i>Nature Cancer</i> , 2022, 3, 11-24.	13.2	21
66	Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas. <i>Pediatric Blood and Cancer</i> , 2015, 62, 240-245.	1.5	19
67	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 13-20.	2.9	16
68	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Research</i> , 2019, 79, 4026-4041.	0.9	16
69	Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. <i>Nature Cancer</i> , 2022, 3, 629-648.	13.2	16
70	A Partially Thrombosed, Fenestrated Basilar Artery Mimicking an Aneurysm of the Vertebrobasilar Junction. <i>Neurosurgery</i> , 1992, 30, 276-278.	1.1	15
71	Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1589-1595.	4.2	15
72	Longitudinal CSF Iron Pathway Proteins in Posthemorrhagic Hydrocephalus: Associations with Ventricle Size and Neurodevelopmental Outcomes. <i>Annals of Neurology</i> , 2021, 90, 217-226.	5.3	15

#	ARTICLE	IF	CITATIONS
73	Intramedullary spinal cord astrocytomas in children. <i>Pediatric Blood and Cancer</i> , 2004, 43, 617-618.	1.5	14
74	Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. <i>Neuro-Oncology</i> , 2020, 22, 1696-1704.	1.2	14
75	Growth factors in gliomas: antisense and dominant negative mutant strategies. , 1997, 35, 275-285.		13
76	Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. <i>Cancer Gene Therapy</i> , 2000, 7, 486-494.	4.6	13
77	Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. <i>Cancers</i> , 2020, 12, 643.	3.7	13
78	Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. <i>EBioMedicine</i> , 2021, 71, 103571.	6.1	13
79	Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1. <i>BBA Clinical</i> , 2016, 5, 1-15.	4.1	12
80	Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium. <i>Journal of Neuro-Oncology</i> , 2019, 143, 79-86.	2.9	12
81	An Intrasyllian "Fibroma" in a Child with Cystic Fibrosis: Case Report. <i>Neurosurgery</i> , 2000, 46, 744-748.	1.1	11
82	Risk assignment in childhood brain tumors: The emerging role of molecular and biologic classification. <i>Current Oncology Reports</i> , 2002, 4, 114-122.	4.0	11
83	A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10504-10504.	1.6	11
84	Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance. <i>Molecular Cancer Research</i> , 2020, 18, 1004-1017.	3.4	10
85	A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10065-10065.	1.6	10
86	Outcomes in children undergoing posterior fossa decompression and duraplasty with and without tonsillar reduction for Chiari malformation type I and syringomyelia: a pilot prospective multicenter cohort study. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 25, 21-29.	1.3	10
87	Management of Low-Grade Gliomas in Childhood. <i>World Neurosurgery</i> , 2014, 81, 265-267.	1.3	9
88	Diagnostic and Therapeutic Stratification of Childhood Brain Tumors: Implications for Translational Research. <i>Journal of Child Neurology</i> , 2008, 23, 1179-1185.	1.4	8
89	Ependymomas: development of immunotherapeutic strategies. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1089-1098.	2.8	8
90	Shotgun pellet embolization to the posterior cerebral artery. <i>Child's Nervous System</i> , 2016, 32, 1317-1320.	1.1	8

#	ARTICLE	IF	CITATIONS
91	Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 155-166.	1.0	8
92	Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-2 silenced cells. <i>Molecular Carcinogenesis</i> , 2018, 57, 469-482.	2.7	8
93	Predictors of fast and ultrafast shunt failure in pediatric hydrocephalus: a Hydrocephalus Clinical Research Network study. <i>Journal of Neurosurgery: Pediatrics</i> , 2021, 27, 277-286.	1.3	8
94	RASopathy in Patients With Isolated Sagittal Synostosis. <i>Global Pediatric Health</i> , 2019, 6, 2333794X1984677.	0.7	7
95	Management of sagittal synostosis in the Synostosis Research Group: baseline data and early outcomes. <i>Neurosurgical Focus</i> , 2021, 50, E3.	2.3	7
96	Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases. <i>Molecular Oncology</i> , 2022, 16, 219-249.	4.6	7
97	Surgical resource utilization after initial treatment of infant hydrocephalus: comparing ETV, early experience of ETV with choroid plexus cauterization, and shunt insertion in the Hydrocephalus Clinical Research Network. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 26, 337-345.	1.3	7
98	Surgical Options for Pineal Region Tumors. <i>World Neurosurgery</i> , 2012, 77, 302-303.	1.3	6
99	The Incidence of Chiari Malformations in Patients with Isolated Sagittal Synostosis. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2019, 7, e2090.	0.6	6
100	Serial Visual Evoked Potentials in Patients with Craniosynostosis and Invasive Intracranial Pressure Monitoring. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 446e-452e.	1.4	6
101	Cerebrospinal fluid NCAM-1 concentration is associated with neurodevelopmental outcome in post-hemorrhagic hydrocephalus of prematurity. <i>PLoS ONE</i> , 2021, 16, e0247749.	2.5	6
102	The Hydrocephalus Clinical Research Network quality improvement initiative: the role of antibiotic-impregnated catheters and vancomycin wound irrigation. <i>Journal of Neurosurgery: Pediatrics</i> , 2022, 29, 711-718.	1.3	6
103	Tumor-Stromal Interactions in Medulloblastoma. <i>New England Journal of Medicine</i> , 2013, 368, 1942-1943.	27.0	5
104	Treatment strategies for hydrocephalus related to Dandy-Walker syndrome: evaluating procedure selection and success within the Hydrocephalus Clinical Research Network. <i>Journal of Neurosurgery: Pediatrics</i> , 2021, 28, 93-101.	1.3	5
105	Corrigendum to: LTBK-01. Updates On The Phase II And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. <i>Neuro-Oncology</i> , 2022, 24, 1404-1404.	1.2	5
106	New Delivery Approaches for Pediatric Brain Tumors. <i>Journal of Neuro-Oncology</i> , 2005, 75, 315-326.	2.9	4
107	Ataxia resulting from posterior fossa tumors of childhood and other mass lesions. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 103, 161-173.	1.8	4
108	The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 17, 453-459.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Hydrocephalus treatment in patients with craniosynostosis: an analysis from the Hydrocephalus Clinical Research Network prospective registry. <i>Neurosurgical Focus</i> , 2021, 50, E11.	2.3	4
110	Clinical Utility of GliOSeq Next-Generation Sequencing Test in Pediatric and Young Adult Patients With Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 694-702.	1.7	3
111	Phase 1 trial of p28 (NSC745104), a non-HDM2 mediated peptide inhibitor of p53 ubiquitination in children with recurrent or progressive CNS tumors: A final report from the Pediatric Brain Tumor Consortium.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10059-10059.	1.6	3
112	Syndromic and Systemic Diagnoses Associated With Isolated Sagittal Synostosis. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2019, 7, e2540.	0.6	2
113	Proliferation index as a predictor of prognosis in malignant gliomas of childhood. <i>Cancer</i> , 1997, 79, 849-856.	4.1	2
114	A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: A Pediatric Brain Tumor Consortium report.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2036-2036.	1.6	2
115	Quantitative Sodium (²³ Na) MRI in Pediatric Gliomas: Initial Experience. <i>Diagnostics</i> , 2022, 12, 1223.	2.6	2
116	Recent Advances in the Molecular Characterization of Childhood Brain Tumors: Editorial Comments. <i>Brain Pathology</i> , 1997, 7, 753-754.	4.1	1
117	EPT-19PHASE I TRIAL OF PALBOCICLIB, A CDK4/6 INHIBITOR IN CHILDREN WITH RETINOBLASTOMA PROTEIN (RB1) + RECURRENT CENTRAL NERVOUS SYSTEM (CNS) TUMORS (PBTC 042). <i>Neuro-Oncology</i> , 2016, 18, iii28.1-iii28.	1.2	1
118	ATRT-10. EARLY POST RADIATION CHANGES AND EFFICACY IN CHILDREN WITH ATRT TREATED ON COG ACNS 0333: A COMPARISON OF PROTON VS PHOTON THERAPY. <i>Neuro-Oncology</i> , 2017, 19, iv3-iv3.	1.2	1
119	Isolated Traumatic Diastasis of the Clival Synchrondroses without Clival Fracture. <i>Pediatric Neurosurgery</i> , 2018, 53, 270-274.	0.7	1
120	Appearance of Parasagittal Suture and Bregmatic Bone after Surgical Intervention for Craniosynostosis. <i>FASEB Journal</i> , 2010, 24, 636.7.	0.5	1
121	Endoscopic third ventriculostomy revision after failure of initial endoscopic third ventriculostomy and choroid plexus cauterization. <i>Journal of Neurosurgery: Pediatrics</i> , 2022, 30, 8-17.	1.3	1
122	Childhood gliomas: an overview. <i>Journal of Neuro-Oncology</i> , 1996, 28, 117.	2.9	0
123	Frameless Stereotactic Guidance for Surgery of the Upper Cervical Spine. <i>Neurosurgery</i> , 1997, , .	1.1	0
124	P53 pathway alterations are uncommon in childhood ependymomas. <i>Pediatric Blood and Cancer</i> , 2006, 46, 531-532.	1.5	0
125	MB-52RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY (RAPNO) COMMITTEE GUIDELINES FOR RESPONSE ASSESSMENT IN MEDULLOBLASTOMA AND OTHER LEPTOMENINGEAL SEEDING TUMORS. <i>Neuro-Oncology</i> , 2016, 18, iii109.1-iii109.	1.2	0
126	TMIC-14. AUTO-/PARACRINE SIGNALING OF PI3K/AKT/YKL-40 IN MESENCHYMAL GLIOBLASTOMA PROGRESSION. <i>Neuro-Oncology</i> , 2018, 20, vi258-vi259.	1.2	0

#	ARTICLE	IF	CITATIONS
127	IMMU-18. TARGETING THE PD1 AND TIGIT CHECKPOINT PATHWAYS FOR ADULT AND PEDIATRIC GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi125-vi125.	1.2	0
128	IMMU-16. GUADECITABINE (SGI-110) ENHANCES MHC class I AND TUMOR ANTIGEN EXPRESSION ON MURINE C57BL/6-SYNGENEIC GLIOMA AND DIPG MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi124-vi124.	1.2	0
129	IMMU-17. PEPTIDE VACCINE IMMUNOTHERAPY BIOMARKERS AND RESPONSE PATTERNS IN PEDIATRIC GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi124-vi125.	1.2	0
130	DIPG-11. ACTIVATION OF RAS SIGNALING AND DISTINCT MITOGEN-ACTIVATED PROTEIN KINASES (MAPKs) PROVIDES UNIQUE THERAPEUTIC VULNERABILITIES IN MUTANT HISTONE DIPG. <i>Neuro-Oncology</i> , 2019, 21, ii70-ii70.	1.2	0
131	CSIG-31. ALTERNATIVE RECEPTOR TYROSINE KINASE SIGNALING AS A RESISTANCE MECHANISM TO ERK INHIBITION IN HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi50-vi51.	1.2	0
132	Decompressive Cranial Vault Remodeling in Osteosclerotic Robinow Syndrome. <i>Cleft Palate-Craniofacial Journal</i> , 2021, 58, 126-130.	0.9	0
133	OTME-20. Chitinase-3-like-1 (CHI3L1) Protein Complexes Regulate the immunosuppressive Microenvironment in Glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, ii17-ii18.	0.7	0
134	Migration of Glioblastoma Cells Indicates Invasion Is Mediated by a Network of Proteins Stimulated by HGF/Met and Suppressed by Radicol. <i>FASEB Journal</i> , 2007, 21, A26.	0.5	0
135	Identification of novel chemosensitivity nodes using siRNA synthetic lethal screens. <i>FASEB Journal</i> , 2010, 24, 964.11.	0.5	0
136	A potential role for coamplification of other oncogenes with EGFR in the control of metabolism in glioblastomas. <i>FASEB Journal</i> , 2011, 25, lb318.	0.5	0
137	DIPG-47. HISTONE MUTATIONS ENHANCE RAS MEDIATED ERK5 GROWTH SIGNALING IN DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii296-iii296.	1.2	0
138	MBRS-63. THE ROLE OF THE SWI/SNF COMPLEX SUBUNIT SMARCD3 IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii409-iii409.	1.2	0
139	MEDB-88. BAF60C/SMARCD3-mediated novel neurodevelopmental epigenomic program promotes metastatic dissemination in medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i127-i127.	1.2	0
140	IMMU-06. Landscape of adaptive immunity of childhood brain cancers. <i>Neuro-Oncology</i> , 2022, 24, i82-i82.	1.2	0
141	Hydrocephalus surveillance following CSF diversion: a modified Delphi study. <i>Journal of Neurosurgery: Pediatrics</i> , 2022, 30, 177-187.	1.3	0